국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
RANITIDINE HYDROCHLORIDE
G & A Licensing Limited
300 Base Milligrams
Film Coated Tablet
2009-12-04
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PPA1447/061/002 Case No: 2071035 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to G & A LICENSING LTD BALLYMURRAY, CO. ROSCOMMON, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product ZANTAC 300 MG FILM-COATED TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 04/12/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 04/12/2009_ _CRN 2071035_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zantac 300 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300mg of ranitidine (as hydrochloride) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet _Product imported from Greece_ White, capsule-shaped tablets engraved ‘GXEC3’ on one face and plain on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of duodenal ulcer and benign gastric ulcer including that associated with non-steroidal anti- inflammatory agents. Prevention of non-steroidal anti-inflammatory drug (including aspirin) associated duodenal ulcers, especiall 전체 문서 읽기